Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient men and women age 18 and older~* Diagnosis of BDD within 6 months of study start date based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)~* Score of 24 or higher on the BDD-Yale-Brown Obsessive Compulsive Scale~* Lives within driving distance of Boston, MA or Providence, RI~Exclusion Criteria:~* Suicidal or homicidal tendencies~* Alcohol/drug abuse or dependence within 3 months of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: EXPERIMENTAL): In Phase I, all participants received open-label escitalopram for 14 weeks (at a dosage of 10 mg/d in weeks 1-3, 20 mg/d weeks 4-6, and 30 mg/d thereafter). Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to continue with escitalopram for Phase II of the study (Weeks 16-40)
- Placebo (Type: PLACEBO_COMPARATOR): Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to receive a placebo for Phase II of the study (Weeks 16-40)

Based on this trial design, predict the completion outcome and termination type (if applicable).